Beyond these malignancies, targeting PI3K signaling, including PIK3C2G, has shown therapeutic promise in cancers such as hepatocellular carcinoma, breast cancer, and renal cell carcinoma (30–33). Here, PIK3C2G is linked to breast cancer.